The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
High-dose erlotinib for refractory leptomeningeal metastases (LM) after failure of standard dose EGFR-TKIs.
Takahisa Kawamura
No relevant relationships to disclose
Akito Hata
No relevant relationships to disclose
Takehiro Otoshi
No relevant relationships to disclose
Daichi Fujimoto
No relevant relationships to disclose
Koji Tamai
No relevant relationships to disclose
Jumpei Takeshita
No relevant relationships to disclose
Takeshi Matsumoto
No relevant relationships to disclose
Kazuya Monden
No relevant relationships to disclose
Kazuma Nagata
No relevant relationships to disclose
Kyoko Otsuka
No relevant relationships to disclose
Atsushi Nakagawa
No relevant relationships to disclose
Ryo Tachikawa
No relevant relationships to disclose
Kojiro Otsuka
No relevant relationships to disclose
Reiko Kaji
No relevant relationships to disclose
Shiro Fujita
No relevant relationships to disclose
Nobuyuki Katakami
No relevant relationships to disclose
Keisuke Tomii
No relevant relationships to disclose